Neuropeptides in the skin;Neuropeptídeos na pele

Anais Brasileiros de Dermatologia

Volumn 78, Issue 4, 2003, Pages 483-498

  Kalil Gaspar, Pedro ^a  

^a NONE   (Brazil)

Author keywords

Alopecia; Dermatitis, atopic; Hypersensitivity; Leprosy; Nerve growth factors; Neuropeptides; Psoriasis; Skin

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NEUROPEPTIDE; NEUROPEPTIDE Y; PREPROTACHYKININ; RESINIFERATOXIN; SOMATOSTATIN; SUBSTANCE P; TACHYKININ; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALOPECIA; ATOPIC DERMATITIS; CELL PROLIFERATION; DELAYED HYPERSENSITIVITY; DERMATITIS; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; HYPERSENSITIVITY; IMMUNOCOMPETENT CELL; INFLAMMATION; LANGERHANS CELL; LEPROSY; MAST CELL; NEUROTRANSMISSION; NOMENCLATURE; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; POSTHERPETIC NEURALGIA; PRURITUS; PSORIASIS; REVIEW; SKIN CELL; SKIN NERVE;

EID: 0041329511     PISSN: 03650596     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0365-05962003000400010     Document Type: Review

References (144)

1. Hsieh ST, Choi S, Lin WM, Chang YC, McArthur JC, Griffin JW.: Epidermal denervation and its effects on keratinocytes and Langerhans cells. J Neurocytol 1996; 25:513-24.
2. Hsieh ST, Lin WM.: Modulation of keratinocyte proliferation by skin innervation. J Invest Dermatol 1999; 113:579-86.
3. Kjartansson J, Dalsgaard CJ, Jonsson CE.: Decreased survival of experimental critical flaps in rats after sensory denervation with capsaicin. Plast Reconstr Surg 1987; 79:218-21.
4. Engin C, Demirkan F, Ayhan S, Atabay K, Baran.: Delayed effect of denervation on wound contraction in rat skin. Plast Reconstr Surg 1996; 98:1063-7.
5. Olivari N, Schrudde J, Wahle H.: The surgical treatment of bedsores in paraplegics. Plast Reconstr Surg 1972; 50:477-82.
6. Richards AM, Floyd DC, Terenghi G, McGrouther.: Cellular changes in denervated tissue during wound healing in a rat model. Br J Dermatol 1999; 140:1093-9.
7. Wallengren J, Chen D, Sundler F.: Neuropeptide-containing C-fibres and wound healing in rat skin. Neither capsaicin nor peripheral neurotomy affect the rate of healing. Br J Dermatol 1999; 140:400-8.
8. Jancsó N, Jancsó-Gábor A, Szolcsányi J.: Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemother 1967; 31:138-51.
9. Baluk P.: Neurogenic inflammation in skin and airways. J Invest Dermatol Symp Proc 1997; 2:76-81.
10. Von Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol London 1931; 72:74-87.
11. Marchand JE, Zaccheo TS, Connelly CS, Kream RM.: Selective in situ hybridization histochemical analyses of alternatively spliced mRNAs encoding beta- and gamma-preprotachykinins in rat central nervous system. Brain Res 1993; 17:83-94 (Abstract).
12. Scholzen T, Armstrong C, Burnett N, Luger T, Olerud J, Ansel J.: Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 1998; 7:81-96.
13. Wallengren J.: Vasoactive peptides in the skin. J Invest Dermatol Symp Proc 1997; 2:49-55.
14. Wallengren J, Hakánson R.: Effects of substance P, neurokinin A and calcitonin gene-related peptide in human skin and their involvement in sensory-mediated responses. Eur J Pharmacol 1987; 143:267-73.
15. Foreman JC.: Peptides and neurogenic inflammation. Br Med Bulletin 1987; 43(2):386-400.
16. Lotti T, Hautmann G, Panconesi.: Neuropeptides in skin. J Am Acad Dermatol 1995; 33:482-96.
17. Zancanaro C, Merigo F, Crescimano C, Orlandini S, Osculati A.: Immunohistochemical evidence suggests intrinsic regulatory activity of human eccrine sweat glands. J Anat 1999; 194:433-44.
18. Johansson O, Fantini F, Hu H.: Neuronal structural proteins, transmitters, transmitter enzimes and neuropeptides in human Meissner corpuscles: a reappraisal using immunohistochemistry. Arch Dermatol Res 1999; 291:419-24.
19. Amann R, Sirinathsinghji DSJ, Donnerer J, Liebmann I, Schuligoi R.: Stimulation by nerve growth factor of neuropeptide synthesis in the adult rat in vivo: bilateral response to unilateral intraplantar injections. Neurosci Lett 1996; 203:171-4.
20. Donnerer J, Schuligoi R, Stein C.: Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue - evidence for a regulatory function of nerve growth factor in vivo. Neuroscience 1992; 49:693-8.
21. Donnerer J, Amann R, Schuligoi R, Skofitsch G.: Complete recovery by nerve growth factor of neuropeptide content and function in capsaicin-impaired sensory neurons. Brain Res 1996; 741:103-8.
22. Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS, Petersen LJ, Schmelz M.: Acute effects of substance P and calcitonin gene-related peptide in human skin - a microdialysis study. J Invest Dermatol 2000; 115:1015-20.
23. Bull HA, Hothersall J, Chowdhury N, Cohen J, Dowd PM.: Neuropeptides induce release of nitric oxide from human dermal microvascular endothelial cells. J Invest Dermatol 1996; 106:655-60.
24. Bowden JJ, Baluk P, Lefevre PM, Vigna SR, McDonald DM.: Substance P (NK1) receptor immunoreactivity on endothelial cells of the rat tracheal mucosa. Am J Physiol 1996; 270:L404-14.
25. Cao T, Gerard NP, Brain S.: Use of NK1 knockout mice to analyse substance P-induced edema formation. Am J Physiol 1999; 277(2-Pt2):476-81.
26. Hägermark Ö, Hökfelt T, Pernow B.: Flare and itch induced by substance P in human skin. J Invest Dermatol 1978; 71:233-5.
27. Nilsson J, von Euler AM, Dalsgaard CJ.: Stimulation of connective tissue cell growth by substance P and substance K. Nature (Lond.) 1985; 315:61-3 (Abstract).
28. Katayama I, Nishioka K.: Substance P augments fibrogenic cytokine-induced fibroblast proliferation: possible involvement of neuropeptide in tissue fibrosis. J Dermatol Sci 1997; 15:201-6.
29. Crowe R, Parkhouse N, McGrouther D, Burnstock G.: Neuropeptides-containing nerves in painful hypertrophic human scar tissue. Br J Dermatol 1994; 130:444-52.
30. Parenti A, Amerini S, Ledda F, Maggi CA, Ziche M.: The tachychinin NK1 receptor mediates the migration-promoting effect of substance P on human skin fibroblasts in culture. Naunin-Schmiedebergs Arch Pharmacol 1996; 353:475-81.
31. Wiedermann CJ, Auer B, Sitte B, Reinisch N, Schratzberger P, Kahler CM.: Induction of endothelial cell differentiation into capillary-like structures by substance P. Eur J Pharmacol 1996; 298:335-8.
32. Paus R, Heinzelmann T, Robiseck S.: Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Arch Dermatol Res 1997; 287:500-2 (Abstract).
33. Ansel JC, Brown JR, Payan DG, Brown MA.: Substance P selectively activates TNF-alpha gene expression in murine mast cells. J Immunol 1993; 150:4478-85.
34. Huttunen M, Harvima I, Ackermann L, Harvima R, Naukkarinen A, Horschmanheimo M.: Neuropeptide- and capsaicin-induced histamine release in skin monitored with the microdialysis technique. Acta Derm Venereol 1996; 76:205-9.
35. Piotrowski W, Foreman JC.: On the actions of substance P, somatostatin and vasoactive intestinal polypeptide on rat peritoneal mast cells and in human skin. Naunin Schmiedebergs Arch Pharmacol 1985, 331:364-8.
36. Columbo M, Horowitz EM, Kagey-Sobotka A, Lichtenstein LM.: Substance P activates the release of histamine from human skin mast cells through a pertussis toxin-sensitive and protein kinase C-dependent mechanism. Clin Immunol Immunopathol 1996; 81:68-73.
37. Ansel JC, Armstrong CA, Song I, Quinlan KL, Olerud JE, Caughman SW, Bunnet NW.: Interactions of the skin and nervous system. J Invest Dermatol Proc 1997; 2:23-6.
38. Quinlan KL, Song IS, Naik SM, Letran EL, Olerud JE, Bunnet NW, Armstrong CA, Caughman SW, Ansel JC.: VCAM-1 expression on human dermal microvascular endothelial cells is directly and specifically up-regulated by substance P. J Immunol 1999; 162:1656-61.
39. Quinlan KL, Naik SM, Cannon G, Armstrong CA, Bunnet NW, Caughman SW, Ansel JC.: Substance P activates coincident NF-AT- and NF-kappaB-dependent adhesion molecule gene expression in microvascular endothelial cells through intracellular calcium mobilization. J Immunol 1999; 163:5656-65.
40. Bozic CR, Lu B, Hopken UE, Gerard C, Gerard NP.: Neurogenic amplification of immune complex inflammation. Science 1996; 273:1722-5.
41. Smith CH, Barker JN, Morris RW, MacDonald DM, Lee TH.: Neuropeptides induce rapid expression of endothelial cell adhesion molecules and elicit granulocytic infiltration in human skin. J Immunol 1993; 151:3274-82 (Abstract).
42. Viac J, Gueniche A, Doutremepuich JD, Reichert U, Claudy A, Schmitt D.: Substance P and keratinocyte activation markers: an in vitro approach. Arch Dermatol Res 1996; 288:85-90.
43. Payan DG, Brewster DR, Missirian-Bastin A, Goetzl EJ.: Substance P recognition by a subset of human T-lymphocytes. J Clin Invest 1984; 74:1532-9. (Abstract).
44. Stanisz AM, Befus D, Bienenstock J.: Differential effects of vasoactive intestinal polypeptide, substance P and somatostatin on immunoglobulin synthesis and proliferation by lymphocytes from Peyer's patches, mesenteric lymphnodes and spleen. J Immunol 1986; 136:152-6.
45. Ramershawar P, Gascon P, Ganea D.: Immuno-regulatory effects of neuropeptides stimulation of interleukin-2 production by substance P. J Neuroimmunol 1992; 37:65-74 (Abstract).
46. Croitoru K, Ernst PB, Bienenstock J, Padol I, Stanisz AM.: Selective modulation of the natural killer cell activity of murine intestinal intraepithelial leucocytes by the neuropeptide substance P. Immunology 1990; 71:196-201.
47. Lotz M, Vaughan JH, Carson DA.: Effects of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1989; 241:1218-21 (Abstract).
48. Amann R, Egger T, Schuligoi R.: The tachykinin NK1 receptor antagonist SR140333 prevents the increase of nerve growth factor in rat paw skin induced by substance P or neurogenic inflammation. Neuroscience 2000; 100(3):611-5.
49. Amara SG, Evans RM, Rosenfeld MG.: Calcitonin/calcitonin gene-related peptide transcription unit: tissue-specific expression involves selective use of alternative polyadenylation sites. Mol Cell Biol 1984; 4:2151-60.
50. Wallengren J, Ekman R, Sundler F.: Occurrence and distribution of neuropeptides in human skin. An immunocytochemical study on normal skin and blister fluid from inflammed skin. Acta Derm Venereol (Stockh) 1987; 67:185-92. (Abstract).
51. Gibbins IL, Wattchow D, Coventry B.: Two immunohistochemically identified populations of calcitonin gene-related peptide (CGRP)-immunoreactive axons in human skin. Brain Res 1987; 414:143-8.
52. Hordinsky MK, Ericson MA.: Relationship between follicular nerve supply and alopecia. Dermatol Clinics 1996; 14(4):651-60.
53. Aiyar N, Rand K, Elshourbagy NA.: A cDNA encoding the calcitonin gene-related peptide type 1 receptor. J Biol Chem 1996; 271:11325-9.
54. b. Luebke AE, Dahl GP, Roos BA, Dickerson IM.: Identification of a protein that confers calcitonin gene-related peptide responsiveness to oocytes by using a cystic fibrosis transmembrane conductance regulator assay. Proc Natl Acad Sci USA 1996; 93:2455-60.
55. Naghashpour M, Rosenblatt MI, Dickerson IM, Dahl GP.: Inhibitory effect of calcitonin gene-related peptide on myometrial contractility is diminished at parturition. Endocrinology 1997; 138:4207-14.
56. Goldsmith PC, Leslie TA, Hayes NA, Level NJ, Dowd PM, Foreman JC.: Inhibitors of nitric oxide in human skin. J Invest Dermatol 1996; 106:113-8.
57. Ralevic V, Khalil Z, Dusting GJ, Helme RD.: Nitric oxide and sensory nerves are involved in the vasodilator response to acetylcholine but not calcitonin gene-related peptide in rat skin microvasculature. Br J Pharmacol 199 (ano?); 106:650-5.
58. Cappugi P, Gerini G, Verrone C, et al.: Esperienze preliminari sulláttivitá del CGRP con lo skin window test. G Ital Dermatol Venereol 1990; 125:135-8 (Abstract).
59. Haegerstrand A, Dalsgaard CJ, Jonzon B, et al.: Calcitonin gene-related peptide stimulates proliferation of human endothelial cells. Proc Natl Acad Sci 1990; 87:3299-303 (Abstract).
60. Hara M, Toyoda M, Yaar M et al.: Innervation of melanocytes in human skin. J Exp Med 1996; 184:1385-95.
61. Asahina A, Moro O, Hosoi J, Lerner EA, Xu S, Takashima A, Granstein RD.: Specific induction of cAMP in Langerhans cells by calcitonin gene-related peptide: relevance and functional effects. Proc Natl Acad Sci 1992; 92:8323-7.
62. Torii H, Yan Z, Hosoi J, Granstein R.: Expression of neurotrotic factors and neuropeptide receptors by epidermal Langerhans cells and the Langerhans cell-like line XS52: further support for a functional relationship between Langerhans cells and epidermal nerves. J Invest Dermatol 1997; 109:586-91.
63. Torii H, Hosoi J, Beissert S et al.: Regulation of cytokine expression in macrophages and the Langerhans cell-line XS52 by calcitonin gene-related peptide. J Leucocyte Biol 1997; 61:216-23.
64. Torii H, Tamaki K, Granstein RD.: The effect of neuropeptides/hormones on Langerhans cells. J Dermatol Sci 1999; 20:21-8.
65. b. Fox FE, Kubin M, Cassin M et al.: Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12. J Invest Dermatol 1997; 108:43-8.
66. Torii H, Hosoi J, Asahina A, Granstein RD.: Calcitonin gene-related peptide and Langerhans cell function. J Invest Dermatol Symp Proc 1997; 2:82-6.
67. Girolomoni G, Tigelaar RE.: Capsaicin-sensitive primary sensory neurons are potent modulators of murine delayed-type hypersensitivity reactions. J Immunol 1990; 145:1105-12.
68. Ek L, Theodorsson E.: Tachykinins and calcitonin gene-related peptide in oxazolone-induced allergic contact dermatitis in mice. J Invest Dermatol 1990; 94:761-3.
69. Clementi G, Amico-Roxas M, Caruso A et al.: Effects of CGRP om different models of mouse ear inflammation. Life Sci 1994; 54:PL119-24 (Abstract).
70. Asahina A, Hosoi J, Beissert S, Stratigos A, Granstein RD.: Inhibition of the induction of delayed-type and contact hypersensitivity by calcitonin gene-related peptide. J Immunol 1995; 154:3056-61.
71. Misery L.: Langerhans cells in the neuro-immuno-cutaneous system. J Neuroimmunol 1998; 89:83-7.
72. Umeda Y.: Inhibition of immune responses by calcitonin gene-related peptide. Ann NY Acad Sci 1992; 657:552-4.
73. Wang F, Millet I, Bottomly K, Virgnery A.: Calcitonin gene-related peptide inhibits interleukin-2 production by murine T lymphocytes. J Biol Chem 1988; 154:227-35 (Abstract).
74. Raud J, Lundeberg T, Brodda-Jansen, et al.: Potent antiinflammatory action of calcitonin gene-related peptide. Biochem Biophys Res Commun 1991; 180:1429-35.
75. Misery L.: Skin, Immunity and the nervous system. Br J Dermatol 137:843-50, 1997
76. Fahrenkrug, J.: VIP and autonomic neurotransmission. Pharmacol Ther 1989; 41:515-34 (Abstract).
77. Hartschuh W, Weihe E, Yanaihara N, Reinecke M.: Immunohistochemical localization of vasoactive intestinal polypeptide (VIP) in Merkel cells of various mammals: evidence for a neuromodulator function of the Merkel cell. J Invest Dermatol 1983; 81:361-4 (Abstract).
78. Harmar T, Lutz E.: Multiple receptors for PACAP and VIP. Trends Pharmacol Sci 1994; 15:97-9.
79. Lowman MA, Benyon RC, Church MK. Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells. Br J Pharmacol 1988; 95:121-30.
80. Nilsson SPE, Mäepea O.: Comparison of the vasodilatory effects of vasoactive intestinal polypeptide (VIP) and peptide HI (PHI) in the rabbit and the cat. Acta Physiol Scand 1987; 129:17-26.
81. Williams TJ.: Vasoactive intestinal polypeptide is more potent than prostaglandin E2 as a vasodilator and oedema potentiator in rabbit skin. Br J Pharmacol 1982; 77:505-9.
82. Church MK, Lowman MA, Robinson C, et al.: Interaction of neuropeptides with mast cells. Int Arch Allergy Appl Immunol 1989; 88:70-8.
83. Girolomoni G, Tigelaar RE.: Peptidergic neurons and vasoactive intestinal peptide modulate experimental delayed type hypersensitivity reactions. Ann NY Acad Sci 1992; 650:9-12.
84. Eedy DJ, Shaw C, Armstrong EP, Johnston SF, Buchanan KD.: Vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM) in human eccrine sweat glands: demonstration of innervation, specific binding sites and presence in secretions. Br J Dermatol 1990; 123:65-76.
85. Eedy DJ, Shaw C, Johnston SF, Buchanan KD.: The regional distribution of neuropeptides in human skin as assessed by radioimmunoassay and high-performance liquid chromatography. Clin Exp Dermatol 1994; 19:463-72.
86. Sato K, Sato F.: Effect of VIP on sweat secretion and cAMP accumulation in isolated simian eccrine glands. Am J Physiol 1987; 253:R935-41.
87. Haegerstrand A, Dalsgaard CJ, Jonzon B, et al.: Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes. Proc Natl Acad Sci 1989; 86:5993-6.
88. Pincelli C, Fantini F, Romualdi P, et al.: Substance P is diminished and vasoactive intestinal peptide is augmented in psoriatic lesions and these peptides exert disparate effects on the proliferation of cultured human keratinocytes. J Invest Dermatol 1992; 98:421-7 (Abstract).
89. Wollina U, Huschenbeck J, Knoll B, Sternberg B, Hipler UC.: Vasoactive intestinal peptide supports induced migration of human keratinocytes and their colonization of an artificial polyurethane matrix. Regul Pept 1997; 70:29-36 (Abstract).
90. Taylor AW, Streilen JW, Cousins SW.: Immunoreactive vasoactive intestinal peptide contributes to the immuno-suppressive activity of normal aqueous humor. J Immunol 1994; 153:1080-6.
91. Stanisz AM, Scicchitano R, Biennenstoch J.: The role of vasoactive instestinal peptide and other neuropeptides in the regulation of immune responses in vitro and in vivo. Ann NY Acad Sci 1988; 527:478-85.
92. Narita M, Dun SL, Dun NJ, Tseng LF.: Hyperalgesia induced by pituitary adenylate cyclase-activating polypeptide in the mouse spinal cord. Eur J Pharmacol 1996; 311:121-6.
93. Warren JB, Cockroft JR, Larkin SW, Kajekar R, Macrae A, Ghatei MA, Bloom SR.: Pituitary adenylate cyclase activating polypeptide is a potent vasodilator in humans. J Cardiovasc Pharmacol 1992; 20:83-7 (Abstract).
94. May V, Braas KM: Pituitary adenylate cyclase activating polypeptide (PACAP). Regulation of sympathetic neuron neuropeptide Y and catecholamine expression. J Neurochem 1995; 65:978-87.
95. Dorner GT, Wolzt M, Eichler HG, Schmetterer L.: Effect of pituitary adenylate cyclase activating polypeptide 1-27 on ocular, cerebral and skin blood flow in humans. Naunyn-Schmiedeberg's Arch Pharmacol 1998; 358:657-62.
96. Steinhoff M, MacGregor GP, Radleff-Schlimme A, Steinhoff A, Jarry H, Schmidt WE.: Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin: expression of PACAP-38 is increased in patients with psoriasis. Regul Peptides 1999; 80:49-55.
97. Odum L, Petersen LJ, Skov PS, Ebskov LB.: Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm Res 1998; 47:488-92.
98. Schmidt-Choudhury A, Furuta GT, Galli SJ, Schmidt WE, Wershil BK.: Mast cells contribute to PACAP-induced dermal oedema in mice. Regul Peptides 1999; 82:65-9.
99. Hashim MA, Tadepalli AS.: Cutaneous vasomotor effects of neuropeptide Y. Neuropeptides 1995; 29:263-71 (Abstract).
100. Sundler F, Hákanson R, Ekblad E, Uddman R.: Neuropeptide Y in the peripheral adrenergic and enteric nervous systems. Int Rev Cytol 1986; 102:243-69.
101. Daly RN, Hieble JP.: Neuropeptide Y modulates adrenergic neurotransmission by an endothelium dependent mechanism. Eur J Pharmacol 1987; 138:445-6.
102. Zukowska-Grojec Z, Culman J, Kopin IJ.: Noradrenergic prazosin resistant splanchnic vasoconstriction during immobilization stress in rat: possible role for neuropeptide Y. Am J Physiol 1987; 123:765-71 (Abstract).
103. Edvinsson L, Ekblad E, Hakanson R, et al.: Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol 1983; 5:84-7.
104. Emadi-Khiav B, Mousoli M, Bronner Ch, Landry Y: Human and rat cutaneous mast cells: involvement of a G protein in the response to peptidergic stimuli. Eur J Pharmacol 1995; 272:97-102.
105. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R.: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179:77-9.
106. Johansson O, Hilliges M, Wang L.: Somatostatin-like immunoreactivity is found in dendritic guard cells of human sweat ducts. Peptides 1993; 14:401-3.
107. Gaudillere A, Misery L, Bernard C, Souchier C, Claudy A, Schmitt D.: Presence of somatostatin in normal human epidermis. Br J Dermatol 1997; 137:376-80.
108. Talme T, Schultzberg M, Sundqvist KG, Marcusson JA.: Colocalization of somatostatin- and HLA-DR-like immunoreactivity in dendritic cells of psoriatic skin. Acta Derm Venereol (Stockh) 1997; 77:338-42.
109. Hoyer D, Bell GI, Berelowitz M et al.: Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16:86-8.
110. Lopez F, Esteve JP, Buscail L et al.: Molecular mechanisms of antiproliferative effect of somatostatin: involvement of a tyrosine phosphatase. Metabolism 1996; 45:14-6 (Abstract).
111. Montminy M, Brindle P, Arias J, Ferreri K, Armstrong R.: Regulation of somatostatin gene transcripyion by cyclic adenosine monophosphate. Metabolism 1996; 45:4-7 (Abstract).
112. Olerud JE, Usui ML, Seckin D, Chiu DS, Haycox CL, Song IS, Ansel JC, Bunnet NW.: Neutral endopeptidase expresssion and distributions in human skin wounds. J Invest Dermatol 1999; 112:873-81.
113. Smallridge RC, Gamblin GT, Eil C.: Angiotensin-converting enzyme: characteristics in human skin fibroblasts. Metabolism 1986; 35:899-904 (Abstract).
114. Muns G, Vishwanatha JK, Rubinstein I.: Effects of smokeless tobacco on chemically transformed hamster oral keratinocytes: role of angiotensin 1-converting enzyme. Carcinogenesis 1994; 15:1325-7 (Abstract).
115. Matucci-Cerinic M, Iannone F, Carossino A, Pignone A, Leoncini G, Generini S, Lapadula G, Cagnoni M.: Discrepant expression of neprylisin on fibroblasts in diffuse systemic sclerosis. J Rheumatol 1999; 26:347-51.
116. Paus R, Heinzelmann T, Schultz KD, Furkert J, Fechner K, Czametzki BM: Hair growth induction by substance P. Lab Invest 1994; 71:134-40 (Abstract).
117. Caterina MJ, Schumacher MA, Tominaga M et al.: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389:816-24.
118. Biro T, Acs G, Acs P, Modarres S, Blumberg PM.: Recent advances in understanding vanilloid receptors: a therapeutic target for treatment of pain and inflammation in skin. J Invest Dermatol Symp Proc 1997; 2:56-60.
119. Norton SA.: Useful plants in dermatology. V. Capsicum and capsaicin. J Am Acad Dermatol 1998; 39:626-8.
120. Costa SKP, De Nucci G, Antunes E, Brain SD.: Involvement of vanilloid receptors and purinoceptors in the Phoneutria nigriventer spider venon-induced plasma extravasation in rat skin. Eur J Pharmacol 2000; 391:305-15.
121. Reinmann S, Luger T, Metze D.: [Topical capsaicin for the treatment of itch and pain in dermatological patients]. Hautarzt 2000; 51:164-72.
122. Benrath J, Eschenfelder C, Zimmerman M, Gillardon F.: Calcitonin gene-related peptide, substance P and nitric oxide are involved in cutaneous inflammation following ultraviolet radiation. Eur J Pharmacol 1995; 293:87-96.
123. Benrath J, Zimmerman M, Gillardon F.: Substance P and nitric oxide mediate wound healing of ultraviolet photodamaged rat skin: evidence for an effect of nitric oxide on keratinocyte proliferation. Neurosci Lett 1995; 200:17-20 (Abstract).
124. Scholzen TE, Brzoska T, Kalden DH, O'Reilly F, Armstrong CA, Luger TA, Ansel JC.: Effect of ultraviolet light on the release of neuropeptides and neuroendocrine hormones in the skin: mediators of photodermatitis and cutaneous inflammation. J Invest Dermatol Symp Proc 1999; 4:55-60.
125. Toyoda M, Luo Y, Makino T, Matsui C, Morohashi M.: Calcitonin gene-related peptide upreggulates melanogenesis and enhances melanocyte dendricity via induction of keratinocyte-derived melanotrophic factors. J Invest Dermatol Symp Proc 1999; 4:116-25.
126. Misery L.: The neuro-immuno-cutaneous system and ultraviolet radiation. Photodermatol Photoimmunol Photomed 2000; 16:78-81.
127. Di Marco E, Marchisio PC, Bondanza S, Franzi AT, Cancedda R, De Luca M.: Growth-regulated synthesis and secretion of biologically active nerve growth factor by human keratinocytes. J Biol Chem 1991; 266:21718-22.
128. Raychadhuri S, Jiang WY, Farber EM.: Psoriatic keratinocytes express high levels of nerve growth factor. Acta Derm Venereol 1998; 78:84-6.
129. Chan J, Smoller BR, Raychaudhuri S, Jiang WY, Farber EM.: Arch Dermatol Res 1997; 289:611-16.
130. Pergolizzi S, Vaccaro M, Magaudda L, Mondello MR, Arco A, Bramanti P, Cannavò SP, Guarneri B.: Immunohistochemical study or epidermal nerve fibres in involved and uninvolved psoriatic skin using confocal laser scanning microscopy. Arch Dermatol Res 1998; 290:483-9.
131. Krogstad AL, Lönroth P, Larson G, Wallin BG.: Nerve-induced histamine release is of little importance in psoriatic skin. Br J Dermatol 1998; 139:403-9.
132. Artemi P, Seale P, Satchell P, Ware S.: Cutaneous cascular response to calcitonin gene-related peptide in psoriasis and normal subjects. Australasian J Dermatol 1997; 38:73-6.
133. Staniek V, Misery L, Peguet-Navarro J et al.: Binding and in vitro modulation of human epidermal Langerhans cell functions by substance P. Arch Dermatol Res 1997; 289:285-91 (Abstract).
134. Hosoi J, Murphy GF, Egan CL et al.: Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. Nature 1993; 363:159-63 (Abstract).
135. Rukwied R, Heyer G.: Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients. Exp Dermatol 1999; 8:39-45.
136. Wallengren J, Ekman R, Moller H.: Substance P and vasoactive intestinal peptide in bullous and inflammatory disease. Acta Derm Venereol (Stockh) 1986; 66:23-8 (Abstract).
137. Tobin D, Nabarro G, De La Faille HB.: Increased number of nerve fibers in atopic dermatitis. J Allergy Clin Immunol 1992; 90:613-22.
138. Pincelli C, Fantini F, Massimi P et al.: Neuropeptides in skin from patients with atopic dermatitis: an immunohistochemical study. Br J Dermatol 1990; 122:745-50.
139. Karanth SS, Springall DR, Lucas S, Levy D, Aschby P, Levene MM et al.: Changes in nerves and neuropeptides in skin from 100 leprosy patients investigated by immunocytochemistry. J Pathol 1989; 157:15-26.
140. Antunes SLG, Sarno EN, Holmkvist G, Johansson O.: Immunohistochemical screening of neuropeptides in cutaneous macular lesions of leprosy (Correspondence). Acta Derm Venereol (Stockh) 1993; 74:235-6.
141. Hordinsky M, Ericson M, Snow D, Boeck C, Lee WS.: Peribulbar innervation and substance P expression following nonpermanent injury to the human scalp hair follicle. J Invest Dermatol Symp Proc 1999; 4:316-9.
142. Daly T.: Alopecia areata has low plasma levels of the vasodilator/immunomodulator calcitonin gene-related peptide. Arch Dermatol 1998; 134:1164-5.
143. Atkin DH, Levine N, Walter FG.: Single patch of hair at a denervated site in a patient with alopecia universalis. J Am Acad Dermatol 1997; 37:796-7.
144. Maurer M, Peters EMJ, Botchkarev VA, Paus R.: Intact hair follicle innervation is not essential for anagen induction and development. Arch Dermatol Res 1998; 290:574-8.